Official websites use .gov
Secure .gov websites use HTTPS
Adjuvant chemotherapy use and health care costs after introduction of genomic testing in breast cancer
Adjuvant chemotherapy use and health care costs after introduction of genomic testing in breast cancer
- Collection:
- Health Policy and Services Research
- Series Title(s):
- Research brief (Leonard Davis Institute of Health Economics)
- Author(s):
- Epstein, Andrew J., author
Wong, Yu-Ning, author
Mitra, Nandita, author
Vachani, Anil, author
Hin, Sakhena, author
Yang, Lin, author
Smith-McLallen, Aaron, author
Armstrong, Katrina, author
Groeneveld, Peter W., author - Contributor(s):
- Leonard Davis Institute of Health Economics, issuing body.
- Publication:
- Philadelphia, PA : Leonard Davis Institute of Health Economics, 2016
- Language(s):
- English
- Format:
- Text
- Subject(s):
- Breast Neoplasms -- drug therapy
Breast Neoplasms -- economics
Breast Neoplasms -- genetics
Chemotherapy, Adjuvant -- economics
Chemotherapy, Adjuvant -- statistics & numerical data
Genetic Testing -- economics
Genetic Testing -- statistics & numerical data
Neoplasm Recurrence, Local -- diagnosis
Neoplasm Recurrence, Local -- economics
Neoplasm Recurrence, Local -- genetics
Pharmacogenetics -- economics
United States - Genre(s):
- Technical Report
- Abstract:
- KEY FINDINGS: Genomic testing in patients with early-stage breast cancer is associated with decreased use of chemotherapy and lower costs in younger patients, and slightly increased use of chemotherapy and higher costs in older patients. Genomic testing in actual practice may "rule out" chemotherapy in younger women, and "rule in" chemotherapy in older women. THE QUESTION. The promise of personalized genomic testing is that it can reduce unnecessary care and costs by predicting which patients are most likely to benefit from a treatment. After surgery, women with early-stage breast cancer face the decision of whether to undergo expensive and potentially toxic chemotherapy to prevent recurrence, although most will not have a recurrence. The 21-gene recurrence score test (RS) was developed in 2004 to predict this risk, and its use in clinical medicine is increasing. In this study of actual treatment patterns, LDI Senior Fellows Andrew Epstein and Peter Groeneveld and colleagues investigate how genomic testing of women with early-stage breast cancer affects subsequent chemotherapy use and medical spending in the year after diagnosis. Journal of Clinical Oncology December 2015.
- Copyright:
- Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
- Extent:
- 1 online resource (1 PDF file (2 pages))
- Illustrations:
- Illustrations
- NLM Unique ID:
- 101679516 (See catalog record)
- Permanent Link:
- http://resource.nlm.nih.gov/101679516